This method identified 10 genes: CDC2, CCNA2, IGF1, EGR1, SRF, CTGF, CCL2, CAV1, SMAD4, and AURKA. Since those genes have a large number of downstream targets, they likely drive prostate cancer development and consequently are the best candidates for experimental verification. The gene discussed is AURKA; the disease is prostate carcinoma.